Task Force recommended against PSA screening of all men regardless of age in 2012, a recommendation endorsed by the American Academy of Family Physicians and the American College of Preventive Medicine. By 2013, the American Cancer Society, the American Urological Association, and the American College of Physicians had recommended offering PSA screening to men between 50 and 69 years of age with at least 10 years of remaining life expectancy, but only after a process of informed and shared decision-making. The objective of this study was to evaluate the rate of PSA screening and its trend in different age groups from 2010 through 2015 using large databases covering all men insured by Medicare plus one-third of all privately insured men in the US. Claims data for men under 65 years of age were collected using Truven Health Analytics' MarketScan database for commercial claims and encounters in 2010 to 2015 (9.9-16.6 million men). For men aged 65 years or older, claims data for the entire Medicare-insured population were evaluated using the Centers for Medicare and Medicaid Services virtual research data center encompassing 17.7-21.8 million men. A two-sided Poisson regression was used to determine P for trend using Bonferroni correction to adjust for the number of age groups. To consider PSA testing for screening only, all claims with any one or more of 62 prostate or urinary conditions implying use of testing for purposes other than screening were deleted. PSAbased screening rates in 2010 to 2015 were as follows: 2% in men age 30-39, 5%-6% in men age 40-49, 29%-31% in men age 50-59, 33%-36% in men age 60-64, 9%-12% in men age 65-69, 11%-14% in men age 70-74, and 6%-9% in men older than 74. There were no significant temporal trends in men aged 30-39 years (P = .18), 50-59 years (P = .08), 65-69 years (P = .16), 70-74 years (P = .05), and older than 74 years (P = .16). There were significant downward trends in men aged 40-49 years (P = .005) and 60-64 years (P = .003). For all age groups, PSA screening rate decreased from 2010 to 2015 by 1%, 6%, 2%, 6%, 9%, 13%, and 10%, respectively, for men aged 30-39, 40-49, 50-59, 60-64, 65-69, 70-74, and greater than 74 years (1%-13% decrease in PSA screening rate for the seven age cohorts). All medical organizations recommend against PSA screening of men younger than 50 and older than 69, but a substantial proportion of younger (2%-6%) and older (6%-14%) men still are screened with PSA, contrary to all existing practice guidelines. Further research is needed to understand the reasons for overuse of PSA screening in order to identify more effective means to prevent it. We created a laboratory administration curriculum that is based on the milestones and that allows for objective evaluation of resident achievements. In addition to the usual shadowing of a laboratory director (rounds, meetings, quality assurance/quality control, and validation/verification activities), residents were asked to do an inspection of a laboratory section, complete human subjects research, College of American Pathologists utilization modules, assay verification exercises, and online learning modules targeting various aspects of CLM including finance and regulation. Residents were required to obtain a score >80% to achieve level 3-4 in the milestones. The modules address different topics present in the milestones and are simulation, interactive, and scenario/ case based. Results: Fourteen residents from two institutions took and evaluated the laboratory administration curriculum. The printed certificates from the online modules showed a range in scores (58%-100%) with a mode of 100% correct answers. Of all the activities the residents performed during the rotation, the online modules were found to rank highest (most helpful) by all residents. Verification exercises and conversations with faculty were also considered very helpful; however, residents suggested decreasing the number of meetings to which laboratory directors take them. A 25-question knowledge assessment was performed before the rotation, and the average score was 12.4 (range 9-16.5), while the average score on the same knowledge assessment at the end of the rotation was 20.8 (range 12-25).
training is crucial to running a clinical laboratory, and is prominently represented in the Pathology Systems-Based Practice (SBP) milestones of the Accreditation Council for Graduate Medical Education. However, there is a lack of readily available, adaptable curricula with objective measurements of mastery of CLM concepts. Method: We created a laboratory administration curriculum that is based on the milestones and that allows for objective evaluation of resident achievements. In addition to the usual shadowing of a laboratory director (rounds, meetings, quality assurance/quality control, and validation/verification activities), residents were asked to do an inspection of a laboratory section, complete human subjects research, College of American Pathologists utilization modules, assay verification exercises, and online learning modules targeting various aspects of CLM including finance and regulation. Residents were required to obtain a score >80% to achieve level 3-4 in the milestones. The modules address different topics present in the milestones and are simulation, interactive, and scenario/ case based. Results: Fourteen residents from two institutions took and evaluated the laboratory administration curriculum. The printed certificates from the online modules showed a range in scores (58%-100%) with a mode of 100% correct answers. Of all the activities the residents performed during the rotation, the online modules were found to rank highest (most helpful) by all residents. Verification exercises and conversations with faculty were also considered very helpful; however, residents suggested decreasing the number of meetings to which laboratory directors take them. A 25-question knowledge assessment was performed before the rotation, and the average score was 12.4 (range 9-16.5), while the average score on the same knowledge assessment at the end of the rotation was 20.8 (range 12-25).
Conclusion:
The multi-modal CLM training described here is an easily adoptable, objective system for teaching CLM. It was well liked by residents and provided an objective measurement of mastery of concepts for faculty.
Utilization and Diagnostic Yield of Paraneoplastic Panel Testing at an Academic Tertiary Care Facility
Armen Khararjian, Timothy Amukele; Johns Hopkins University, Baltimore, MD Background: The cost of healthcare in the United States has risen dramatically and now sits at almost 18% of GDP. To combat these rising costs and bend the "cost curve," an emphasis has been placed on value-based care where reimbursements are directly tied to the outcomes of patients. For more than 30 years, the paraneoplastic panel © American Society for Clinical Pathology AJCP / Meeting AbstrActs (PNP) has been a key part of the diagnostic approach for patients who present with neurological symptoms of undetermined etiology, especially those with cancer or risk factors for cancer. Like other costly, complex tests, it presents a good template for utilization optimization. Many reports have been written on the utility of PNP testing in specific diseases (eg, motor neuron disease). However, the literature is scant on the use and utilization of the PNP for an entire hospital. Methods: We performed a one-year retrospective chart review of all PNP orders, in a 700-bed academic tertiary center in the Eastern United States. For all orders, we determined if there was a positive finding, and if appropriate clinical actions were taken in response to the results. Results: A total of 248 samples were sent out for PNP evaluation. The cost per test panel was $871. Of the 248 samples, 27(10.8%) had a positive finding. Six of the 27 (22.2%) had a history of malignancy (pituitary adenoma, thymic carcinoma [2], prostate adenocarcinoma, renal cell carcinoma, and squamous cell carcinoma of the tongue). Nine different autoantibodies were detected. Fifteen of the 27 (55.5%) cases were deemed to have appropriate clinical follow-up. Seven of the 27 (25.9 %, 2.8% overall) led to further action by the clinical team. Conclusions: Our expert clinicians who ordered PNP tests obtained a positive result in 11% of patients. This positivity rate suggests that the patients were appropriately selected for testing. However, in the three-quarters of patients with positive results and no history of malignancy, there was no subsequent referral to attempt to diagnose a neoplasm. These patients represent a group where appropriate response to laboratory results could improve test utility and save costs. In addition, these results can be used for comparison and to help establish utilization guidelines for PNP testing at other institutions.
Computerized Approach to Antibody Identification in Pretransfusion Testing
Reyhan Gedik, Michael Vonplato, Karen Quillen; Boston Medical Center, Boston, MA Background: Antibody screening and identification are key components of pre-transfusion compatibility testing.
Patient's plasma is tested against one or more panels of reagent red blood cells with known antigen phenotype. Pathology residents and lab technologists use a "crossout" method to identify the patient's allo-antibody(ies), based on the pattern of reaction of patient's plasma with the reagent cells. Manual interpretation is time-consuming, and prone to human error. Methods: We designed a spreadsheet to automate the enumeration and dosage of "rule-out" cells, non-reactive with the patient's plasma. An antigen is completely ruled out if two homozygous cells, or one homozygous and two heterozygous cells expressing a particular antigen are non-reactive with patient's plasma. An antigen specificity is "ruled in" when it is not ruled out, and when it explains two to three positive reactions (between patient plasma and reagent cells). For rule-outs that are incomplete, the number of additional cells needed is indicated. Results: We validated our spreadsheet on 25 panels with 100% concordance compared to the manual approach. Antibody specificities identified included anti-D, E, e, C, c, K, Fy(a), Jk(a), Jk(b), M and S. With this method, preliminary antibody interpretation takes less than one minute per case. Limitations of this approach include the lack of consideration of reaction strength (1+ vs 4+), and the need to enter the phenotypes of each new lot of panel cells. An example spreadsheet can be viewed at https:// goo.gl/TpKoyn. Conclusion: A computerized approach to antibody identification reduces time spent on manual cross-outs, reduces human error, and simplifies the initial steps of teaching antibody identification to pathology residents and medical technologists.
71

A Comparison of Urinary Cell Cycle Markers of Acute Kidney Injury ([IGFBP7]*[TIMP2]) and the Product of Classic Urinary Markers [Albumin]*[Creatinine]
Rajeevan Selvaratnam, Beth Stodardt, Ashlinn Milligan; BayCare Health System, Clearwater, FL To evaluate the urinary tissue inhibitor ofmetalloproteinases-2 (TIMP2) and insulin-like growth factor binding protein 7 (IGFBP7) as markers of acute kidney injury (AKI). The test, approved and marketed as Nephrocheck measures both cell cycle biomarkers with the results reported as a product of the two measurement and normalized by 1,000 (ie, [TIMP2] [IGFBP7]/1,000). Several biomarkers for AKI have been proposed in the past, including NGAL, KIM, cystatin, and urinary albumin. However, Nephrocheck is a test that employs a multimarker approach to assessing AKI. Therefore, our goal was to evaluate also the product of two classical markers (urinary albumin and urinary creatinine) normalized by a factor of 1,000 (PACU), ie, (ALBUMIN) (Creatinine)/1,000. PACU, or product of urinary albumin and urinary creatinine, was normalized by a factor of 1,000 for comparative purposes with Nephrocheck. Although creatinine is often used to normalize albumin in urine (ie, albumin:creatinine ratio [ACR]), we reasoned that urine creatinine is also a measure of kidney injury and in a multimarker approach would hypothetically enhance the overall predictive power of AKI. To evaluate the utility of PACU and Nephrocheck, we evaluated 16 patients subject to Nephrochec test, based on the
